<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008380</url>
  </required_header>
  <id_info>
    <org_study_id>3772</org_study_id>
    <nct_id>NCT05008380</nct_id>
  </id_info>
  <brief_title>Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia</brief_title>
  <acronym>EpCOT</acronym>
  <official_title>Open-label, Controlled, Randomized Clinical Trial on the Efficacy of Early Prone-positioning in Patients With Mild Pneumonia Due to SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate if the early prone-positioning in awake patients with mild&#xD;
      Covid-19 pneumonia can reduce the need of high-flow oxygen-therapy, invasive or non-invasive&#xD;
      ventilation and prevent the worsening of clinical conditions.&#xD;
&#xD;
      Patients will be randomized on a 1:1 ratio and stratified based on the onset of symptoms (&lt;10&#xD;
      days; &gt;10 days) and need of oxygen therapy (no need; need).&#xD;
&#xD;
      One branch of patients (interventional) will undergo standard of care treatment +&#xD;
      prone-positioning cycles, the other one (controll) will undergo standard of care treatment&#xD;
      alone.&#xD;
&#xD;
      Patients will be evaluated evaluated on the day of the enrolment, on day 1, day 3, day 7 and&#xD;
      every 7 days until the patient dismissal or until day 28 (whichever occurs first).&#xD;
&#xD;
      Adverse events and concurrent medications will be noted as well.&#xD;
&#xD;
      The analysis will be conducted according to &quot;intention to treat&quot; criteria; primary outcomes&#xD;
      will be calculated using survival-based methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective, unicentred, open, controlled study, patients will be randomized on a 1:1&#xD;
      ratio using casual permutation blocks, identifying two branches of treatment: standard of&#xD;
      care; standard of care + prone positioning. Patients will be stratified in 4 strata based on&#xD;
      the onset of symptoms (&lt;10 days; &gt;10 days) and need of oxygen therapy (no need; need).&#xD;
&#xD;
      In order to obtain statistical significance, the sample size will include 96 patients.&#xD;
&#xD;
      Patients in the SOC + prone-positioning branch will undergo cycles of prone-positioning&#xD;
      following this scheme: 3-6 hours of prone-positioning twice a day. The actual length of the&#xD;
      cycles will be registered during the study.&#xD;
&#xD;
      Data will be collected using a dedicated CRF, which will include recording of adverse events&#xD;
      and concurrent medications.&#xD;
&#xD;
      Patients will be evaluated on the day of the enrolment, on day 1, day 3, day 7 and every 7&#xD;
      days until the patient dismissal or until day 28 (whichever occurs first). If dismissal&#xD;
      occurs before day 28, a follow-up interview will be conducted in presence or on the phone to&#xD;
      collect the remaining data.&#xD;
&#xD;
      The analysis will be conducted according to &quot;intention to treat&quot; criteria; primary outcomes&#xD;
      will be calculated using survival-based methods (Kaplan-Meier curves with log-rank test and&#xD;
      Cox regression), while secondary outcomes will be evaluated using both survival-based methods&#xD;
      and proportional odds model.&#xD;
&#xD;
      The occurrence of adverse events and the causes of withdrawal from the study in the two&#xD;
      branches of treatment will be compared using chi-square test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accomplishment of the end-points</measure>
    <time_frame>0-28 days</time_frame>
    <description>the occurence of the first of the following end-points: death, start of high flow oxygen therapy, CPAP, meccanichal ventilation, P/F &lt;200</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of recovery</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of weaning from oxygen</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation of the clinical condition</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse event</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and duration of prone positioning cycles</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Standard of care + prone positioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>prone positioning</intervention_name>
    <description>3-6 hours of prone-positioning twice a day</description>
    <arm_group_label>Standard of care + prone positioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years&#xD;
&#xD;
          -  positive PCR for Sars-Cov-2 Rna on any respiratory samples within 7 days from&#xD;
             enrollment&#xD;
&#xD;
          -  imaging positive for pulmonary involvement or clinical evidence of respiratory&#xD;
             involvement ( new onest of hypoxemia with 02 &lt;80mmHg or SpO2 &lt; 94% in air or need for&#xD;
             oxygen therapy in oreder to mantaine SpO2 &gt; 93%.&#xD;
&#xD;
          -  need of hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  start of prone-positioning cycles before being enrolled in the study&#xD;
&#xD;
          -  SpO2/FiO2 &lt;200&#xD;
&#xD;
          -  need of high-flow oxygen therapy (HFNC) or need of non-invasive ventilation and/or&#xD;
             CPAP or indications for intubation and mechanical ventilation&#xD;
&#xD;
          -  relative or absolute contraindications for prone positioning (eg facial fractures,&#xD;
             advanced pregnancy, mental status alterations, spinal instability...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Bonfanti</last_name>
    <role>Principal Investigator</role>
    <affiliation>asst-monza Ospedale San Gerardo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Bonfanti</last_name>
    <phone>0392339310</phone>
    <email>paolo.bonfanti@unimib.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asst-Monza Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Bonfanti</last_name>
      <phone>0392339310</phone>
      <email>p.bonfanti@asst-monza.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Lapadula</last_name>
      <phone>0392339320</phone>
      <email>g.lapadula@asst-monza.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>Paolo Bonfanti</investigator_full_name>
    <investigator_title>Director of Infectious Diseases Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

